Modern principles of etiotropic therapy for chronic hepatitis B and C

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review includes an analysis of literature data on the etiotropic therapy of chronic viral hepatitis B and C. In this review, we focused on the efficacy and safety of drugs that have been included in international and Russian guidelines for etiotropic therapy of chronic viral hepatitis B and C. The analysis of the feasibility of using antiviral drugs in real clinical practice was carried out, based on research data on the study of the mechanisms of action, efficacy and possible side effects of these drugs.



Full Text

Restricted Access

About the authors

Nikolay I. Kuznetsov

North-Western State Medical University named after I.I. Mechnikov

Email: Nikolai.Kuznetsov@szgmu.ru
ORCID iD: 0000-0001-5378-3860
SPIN-code: 2558-9273

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint-Petersburg

Irina E. Moiseeva

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: irina.moiseeva@szgmu.ru
ORCID iD: 0000-0003-0236-7028
SPIN-code: 9030-7975
Scopus Author ID: 19836776500
ResearcherId: O-4125-2014

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, Saint-Petersburg

References

  1. Global hepatitis report. 2017 [Internet]. WHO. Available from: http://apps.who.int/iris/bitstream/10665/255017/1/WHO-HIV-2017.06-eng.pdf. Accessed: 23.11.2022.
  2. The Lancet. Towards elimination of viral hepatitis by 2030. Lancet. 2016;388(10042):308. doi: 10.1016/S0140-6736(16)31144-8
  3. Howell J, Pedrana A, Cowie BC, et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol. 2019;34(1):40–48. doi: 10.1111/jgh.14457
  4. European Association for the Study of the Liver, et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–1218. doi: 10.1016/j.jhep.2020.08.018
  5. Maticic M, Mondelli MU. Elimination of viral hepatitis: where do we stand in the year 2020? Clin Microbiol Infect. 2020;26(7):816–817. doi: 10.1016/j.cmi.2020.02.029.
  6. Gosudarstvennyy doklad. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2021 godu [Internet]. Available from: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=21796&ysclid=lc6koh6knz755728296. Accessed: 23.11.2022. (In Russ.)
  7. Mikhaylov MI, Yushchuk ND, Malinnikova EYu, et al. The design of the program for control and elimination of viral hepatitis as public health problem in the Russian federation. Infectious Diseases: News, Opinions, Training. 2018;7(2(25)):52–58. (In Russ.). doi: 10.24411/2305-3496-2018-12005
  8. Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology. 2019;156:297–310. doi: 10.1053/j.gastro.2018.10.048
  9. European Association for the Study of the Liver, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
  10. Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63(1):284–306. doi: 10.1002/hep.28280
  11. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015;313(16):1617–1618. doi: 10.1001/jama.2015.2571
  12. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422–430. doi: 10.1002/hep.23327
  13. Chang T-T, Liaw Y-F, Wu S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893. doi: 10.1002/hep.23785
  14. Liaw YF. Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy. J Hepatol. 2013;59:880–881. doi: 10.1016/j.jhep.2013.05.007
  15. Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, Phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195. doi: 10.1016/S2468-1253(16)30024-3
  16. Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, Phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196–206. doi: 10.1016/S2468-1253(16)30107-8
  17. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58(3):872–880. doi: 10.1002/hep.26436
  18. Sonneveld MJ, Brouwer WP, van der Meer AJ. Posttreatment hepatitis B surface antigen seroreversion: The bane of combination therapy in chronic hepatitis B? Gastroenterology. 2016;150(5):1254–1255. doi: 10.1053/j.gastro.2015.12.047
  19. Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection — EASL Special Conference. J Hepatol. 2015;63(5):1238–1253. doi: 10.1016/j.jhep.2015.06.026
  20. Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013;7(1):88–97. doi: 10.1007/s12072-012-9343-x
  21. Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2):434. doi: 10.3390/v14020434
  22. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. doi: 10.1002/hep.28156
  23. Zeng H, Li L, Hou Z, et al. Direct-acting antiviral in the treatment of chronic hepatitis C: Bonuses and challenges. Int J Med Sci. 2020;17(7):892–902. doi: 10.7150/ijms.43079
  24. Klinicheskiye rekomendatsii “Khronicheskiy virusnyy gepatit C (KHVGS) u vzroslykh” [Internet]. Available from: http://www.consultant.ru/document/cons_doc_LAW_327011/. Accessed: 23.11.2022. (In Russ.)
  25. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi: 10.1016/j.jhep.2016.09.001
  26. Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The first pangenotypic direct-acting antiviral combination for hepatitis C. Ann Pharmacother. 2017;51(1):44–53. doi: 10.1177/1060028016668897
  27. Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int. 2020;40(8):1841–1852. doi: 10.1111/liv.14537
  28. Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71:660–665. doi: 10.1016/j.jhep.2019.05.028
  29. Nelson DR, Cooper JN, Lalezari JP, et al. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135. doi: 10.1002/hep.27726
  30. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378:354–369. doi: 10.1056/NEJMoa1702417
  31. Atsukawa M, Tsubota A, Toyoda H, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019;49(9):1230–1241. doi: 10.1111/apt.15218
  32. Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018;68(4):1298–1307. doi: 10.1002/hep.30046
  33. Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases — Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. doi: 10.1002/hep.31060
  34. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64(2):301–307. doi: 10.1016/j.jhep.2015.10.005
  35. Abergel A, Asselah T, Mallat A, et al. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int. 2020;40(8):1853–1859. doi: 10.1111/liv.14502
  36. Wei L, Jia JD, Wang FS, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019;34(1):12–21. doi: 10.1111/jgh.14509
  37. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371–378. doi: 10.1002/hep.28995
  38. El-Araby HA, Behairy BE, El-Guindi MA, et al. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents. Hepatol Int. 2019;13(6):706–714. doi: 10.1007/s12072-019-09985-w
  39. Burnevich EZ, Gusev DA, Znoyko OO, et al. Efficacy and safety of narlaprevir/ritonavirand daclatasvir combination in the treatment naive, noncirrhotic patients with hepatitis c virus genotype 1b. Klinicheskaya farmakologiya i terapiya. 2018;27(4):35–39. (In Russ.)
  40. Klimova EA, Burnevich EZ, Chulanov VP, et al. Efficacy and safety of narlaprevir/ritonavir and daclatasvir non i.nterferon combination in population of Russian patients with chronic hepatitis C. Ter Arkhiv. 2019;91(8):67–74. (In Russ.). doi: 10.26442/00403660.2019.08.000384
  41. Grushko IP, Romanova EB, Tverdokhlebova TI, et al. Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C. Ter Arkh. 2022;94(8):979–984. (In Russ.). doi: 10.26442/00403660.2022.08.201774
  42. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122–1126. doi: 10.1002/hep.23444

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies